About this item:
569 Views | 823 Downloads
Author Notes:
Corresponding author: Daniel E. Forman (formand@pitt.edu)
Competing interests: Anne Curtis: Advisory board: Daiichi Sankyo, Pfizer, Inc., Janssen Pharmaceuticals, St. Jude Medical; Honoraria: St. Jude Medical; Medtronic, Inc.; Consultant: Medtronic, Inc.
All other authors: No COI
Subjects:
Research Funding:
Mathew Maurer’s institution, Columbia University Medical Center, receives funding for research and serving on advisory boards and DSMBs from Pfizer Inc., Alnylam Pharmaceuticals Inc., ISIS Pharmaceuticals and Prothena Inc.
Keywords:
- Cardiovascular
- Geriatric
- HFpEF
- Cardiology
Improved Cardiovascular Disease Outcomes in Older Adults.
Abstract:
Longevity is increasing and the population of older adults is growing. The biology of aging is conducive to cardiovascular disease (CVD), such that prevalence of coronary artery disease, heart failure, valvular heart disease, arrhythmia and other disorders are increasing as more adults survive into old age. Furthermore, CVD in older adults is distinctive, with management issues predictably complicated by multimorbidity, polypharmacy, frailty and other complexities of care that increase management risks (e.g., bleeding, falls, and rehospitalization) and uncertainty of outcomes. In this review, state-of-the-art advances in heart failure, acute coronary syndromes, transcatheter aortic valve replacement, atrial fibrillation, amyloidosis, and CVD prevention are discussed. Conceptual benefits of treatments are considered in relation to the challenges and ambiguities inherent in their application to older patients.
Copyright information:
© 2016 Forman DE et al.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
